% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koch:292119,
      author       = {J. Koch$^*$ and F. Lyko$^*$},
      title        = {{R}efining the role of {N}6-methyladenosine in cancer.},
      journal      = {Current opinion in genetics $\&$ development},
      volume       = {88},
      issn         = {0959-437X},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2024-01618},
      pages        = {102242},
      year         = {2024},
      note         = {#EA:A130#LA:A130# / DKFZ-ZMBH Alliance},
      abstract     = {N6-methyladenosine (m6A) is the most abundant internal
                      modification of eukaryotic mRNAs. m6A affects the fate of
                      its targets in all aspects of the mRNA life cycle and has
                      important roles in various physiological and
                      pathophysiological processes. Aberrant m6A patterns have
                      been observed in numerous cancers and appear closely linked
                      to oncogenic phenotypes. However, most studies relied on
                      antibody-dependent modification detection, which is known to
                      suffer from important limitations. Novel,
                      antibody-independent, quantitative approaches will be
                      critical to investigate changes in the m6A landscape of
                      cancers. Furthermore, pharmaceutical targeting of the m6A
                      writer Methyltransferase-like 3 (METTL3) has demonstrated
                      the potential to modulate cancer cell phenotypes. However,
                      the enzyme also appears to be essential for the viability of
                      healthy cells. Further refinement of therapeutic strategies
                      is therefore needed to fully realize the potential of
                      m6A-related cancer therapies.},
      subtyp        = {Review Article},
      cin          = {A130},
      ddc          = {610},
      cid          = {I:(DE-He78)A130-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39111230},
      doi          = {10.1016/j.gde.2024.102242},
      url          = {https://inrepo02.dkfz.de/record/292119},
}